According to analyst Frank H. Andersen, Jyske Bank, Novo Nordisk can add billions to its corporate accounts in the future if the combination product – which the group submitted a European registration application for last week – wins approval.
“It doesn’t come as a great surprise. It was expected that the company would submit an application for this product around this time. We estimate peak sales in 2020 of DKK 7.5 billion (USD 1.3 billion), which would make this product a global blockbuster,” he tells Medwatch.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app